These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28975263)

  • 1. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
    Liang F; Zhang S; Wang Q; Li W
    Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of restricted mean survival time in clinical follow-up study].
    Yang ZJ; Lyu JJ; Hou YW; Chen Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.
    Leung TH; Ho JC; Wang X; Pang H
    Chin Clin Oncol; 2023 Oct; 12(5):53. PubMed ID: 37817506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricted mean survival time as a summary measure of time-to-event outcome.
    Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
    Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Tsai FP; Wu TW
    Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
    Abulizi X; Ribaudo HJ; Flandre P
    J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
    Kloecker DE; Davies MJ; Khunti K; Zaccardi F
    Ann Intern Med; 2020 Apr; 172(8):541-552. PubMed ID: 32203984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
    Ueno K; Morita S
    Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
    Monnickendam G; Zhu M; McKendrick J; Su Y
    Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.